Aqr Capital Management LLC Editas Medicine, Inc. Transaction History

Aqr Capital Management LLC

$151 Billion
Q3 2025

A detailed history of Aqr Capital Management LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 687,755 shares of EDIT stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

687,755

Previous 767,615 10.4%

Holding current value

$1.79 Million

Previous $1.69 Million 41.35%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$2.2 - $3.52 $175,692 - $281,107	-79,860 Reduced 10.4%	687,755 $2.39 Million
Q2 2025 Aug 14, 2025	SELL	$0.98 - $2.35 $247,960 - $594,599	-253,021 Reduced 24.79%	767,615 $1.69 Million
Q1 2025 May 15, 2025	SELL	$1.14 - $3.2 $56,449 - $158,454	-49,517 Reduced 4.63%	1,020,636 $1.18 Million
Q4 2024 Feb 14, 2025	BUY	$1.2 - $3.76 $832,747 - $2.61 Million	693,956 Added 184.47%	1,070,153 $1.36 Million
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $1.12 Million - $1.97 Million	330,307 Added 719.78%	376,197 $1.28 Million

Q2 2024 Aug 14, 2024	BUY	$4.67 - $7.28 $115,619 - $180,238	24,758 Added 117.16%	45,890 $214,000
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $148,557 - $233,931	21,132 New	21,132 $156,000
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $63,373 - $85,260	9,158 Added 32.97%	36,933 $288,000
Q2 2023 Aug 14, 2023	SELL	$6.36 - $11.47 $180,833 - $326,126	-28,433 Reduced 50.59%	27,775 $228,000
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $164,825 - $270,332	23,446 Added 71.56%	56,208 $407,000
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $272,579 - $432,786	32,762 New	32,762 $290,000
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $488,501 - $1.04 Million	-48,899 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $489,603 - $960,777	34,773 Added 246.16%	48,899 $930,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $193,522 - $295,714	-7,289 Reduced 34.04%	14,126 $375,000
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $203,261 - $377,537	5,176 Added 31.87%	21,415 $880,000
Q2 2021 Aug 16, 2021	SELL	$31.29 - $56.64 $223,128 - $403,899	-7,131 Reduced 30.51%	16,239 $920,000
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $277,493 - $632,973	6,988 Added 42.66%	23,370 $982,000
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $215,152 - $670,413	-7,948 Reduced 32.67%	16,382 $1.15 Million
Q3 2020 Nov 16, 2020	SELL	$28.06 - $37.16 $318,817 - $422,211	-11,362 Reduced 31.83%	24,330 $683,000
Q2 2020 Aug 17, 2020	SELL	$18.5 - $34.34 $77,589 - $144,021	-4,194 Reduced 10.51%	35,692 $1.06 Million
Q1 2020 May 15, 2020	BUY	$14.88 - $32.78 $593,503 - $1.31 Million	39,886 New	39,886 $791,000
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $364,054 - $636,245	-20,014 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$27.65 - $38.39 $116,710 - $162,044	4,221 Added 26.73%	20,014 $637,000
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $233,110 - $344,352	7,812 Added 97.88%	15,793 $524,000
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $174,704 - $250,124	7,981	7,981 $245,000

Others Institutions Holding EDIT

# of Institutions

226

Shares Held

46.2M

Call Options Held

841K

Put Options Held

304K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $179M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.

Account

Aqr Capital Management LLC Editas Medicine, Inc. Transaction History